The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
Circle Pharma and Verismo feature in coveted sessions.
